MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-24-2026
Country |
 USA |
IPO year |
1992 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBALSPB |
Shares |
1.24 B |
Market Cap[1] |
$ 185 B |
EBITDA (LTM) |
$ 9.3 B |
P/E (LTM) |
24.53 |
P/S (LTM) |
6.39 |
EPS (LTM) |
6.09 |
Gilead Sciences is an American biopharmaceutical company that specializes in the development and production of innovative drugs for the treatment of various diseases.
The company was founded in 1987 and is currently one of the leaders in the field of biotechnology. It conducts research and development in areas such as infectious diseases, oncology, hepatitis, HIV infection, and other areas of medicine.
The company's most well-known and successful product is Sovaldi, which is the first drug to effectively treat chronic hepatitis C. The company also produces drugs for the treatment of blood cancer and HIV infection.
Gilead Sciences actively collaborates with scientific and medical institutions around the world and invests in the development of new methods for treating diseases. The company also provides training programs for medical professionals and patients.
Gilead Sciences continues to grow and expand its activities to help people around the world fight various diseases.
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market |  Germany |
 |
Alector
ALEC
|
$ 2.08 | -14.4 % | $ 214 M | Nasdaq Global Select Market,SPB | USA |
 |
Acer Therapeutics
ACER
|
- | 2.71 % | $ 14 M | Nasdaq Capital Market | USA |
 |
Altimmune
ALT
|
$ 4.2 | -2.67 % | $ 298 M | Nasdaq Global Market | USA |
 |
Apellis Pharmaceuticals
APLS
|
$ 20.24 | -3.44 % | $ 2.55 B | Nasdaq Global Select Market,SPB | USA |
 |
Aptorum Group Limited
APM
|
$ 0.8 | 1.87 % | $ 4.36 M | Nasdaq Global Select Market |  China |
 |
Aprea Therapeutics
APRE
|
$ 0.88 | -3.72 % | $ 3.18 M | Nasdaq Global Select Market,SPB | USA |
 |
Aptevo Therapeutics
APVO
|
$ 7.2 | -1.64 % | $ 1.99 M | Nasdaq Capital Market | USA |
 |
I-Mab
IMAB
|
- | - | $ 866 M | Nasdaq Global Select Market | China |
 |
Aquestive Therapeutics
AQST
|
$ 4.1 | 2.37 % | $ 356 M | Nasdaq Global Market | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | USA |
 |
AgeX Therapeutics
AGE
|
- | -10.17 % | $ 12.2 K | NYSE American | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
$ 8.35 | 1.46 % | $ 225 M | Nasdaq Global Market,SPB |  Israel |
 |
Ardelyx
ARDX
|
$ 6.37 | -2.75 % | $ 1.54 B | Nasdaq Global Market | USA |
 |
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market |  France |
 |
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | USA |
 |
argenx SE
ARGX
|
$ 756.71 | -1.33 % | $ 25 B | Nasdaq Global Select Market |  Niderland |
 |
Armata Pharmaceuticals
ARMP
|
$ 10.91 | 1.58 % | $ 394 M | NYSE American | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
- | - | $ 26.5 M | Nasdaq Global Select Market | USA |
 |
Arcutis Biotherapeutics
ARQT
|
$ 25.33 | -6.1 % | $ 3.22 B | Nasdaq Global Select Market,SPB | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | USA |
 |
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market |  Britain |
 |
Artelo Biosciences
ARTL
|
$ 1.15 | -3.36 % | $ 2.32 M | Nasdaq Global Select Market | USA |
 |
Arvinas
ARVN
|
$ 12.97 | -2.3 % | $ 920 M | Nasdaq Global Select Market,SPB | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
$ 61.74 | -2.42 % | $ 8.26 B | Nasdaq Global Select Market,SPB | USA |
 |
Ascendis Pharma A/S
ASND
|
$ 231.56 | -0.83 % | $ 5 B | Nasdaq Global Select Market |  Danmark |
 |
Alterity Therapeutics Limited
ATHE
|
$ 3.39 | -1.63 % | $ 8.16 B | Nasdaq Capital Market |  Australia |
 |
Actinium Pharmaceuticals
ATNM
|
$ 1.17 | -0.85 % | $ 35.2 M | NYSE American | USA |
 |
Atossa Therapeutics
ATOS
|
$ 4.39 | -0.9 % | $ 553 M | Nasdaq Capital Market | USA |
 |
Atara Biotherapeutics
ATRA
|
$ 5.01 | -7.47 % | $ 37.5 M | Nasdaq Global Select Market,SPB | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
$ 14.14 | -0.21 % | $ 1.9 B | Nasdaq Global Market |  Canada |
 |
ARCA biopharma
ABIO
|
- | 1052.0 % | $ 415 M | Nasdaq Capital Market | USA |
 |
Acorda Therapeutics
ACOR
|
- | -24.86 % | $ 820 K | Nasdaq Global Select Market | USA |
 |
Autolus Therapeutics plc
AUTL
|
$ 1.68 | -1.75 % | $ 429 M | Nasdaq Global Select Market | Britain |
 |
Acasti Pharma
ACST
|
- | 4.01 % | $ 150 M | Nasdaq Capital Market | Canada |
 |
Atea Pharmaceuticals
AVIR
|
$ 4.69 | 0.21 % | $ 395 M | Nasdaq Global Select Market | USA |
 |
Adverum Biotechnologies
ADVM
|
- | - | $ 86.2 M | Nasdaq Global Market | USA |
 |
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX |  Russia |
 |
AIkido Pharma
AIKI
|
- | 1.93 % | $ 17.4 M | Nasdaq Capital Market | USA |
 |
Anavex Life Sciences Corp.
AVXL
|
$ 4.54 | 2.44 % | $ 387 M | Nasdaq Capital Market | USA |
 |
Akero Therapeutics
AKRO
|
- | - | $ 3.67 B | Nasdaq Global Select Market,SPB | USA |
 |
Akouos
AKUS
|
- | 0.23 % | $ 488 M | Nasdaq Global Select Market | USA |
 |
Albireo Pharma
ALBO
|
- | -0.23 % | $ 916 M | Nasdaq Capital Market | USA |
 |
Axon Enterprise
AXON
|
$ 570.5 | 5.18 % | $ 43.2 B | Nasdaq Global Select Market,SPB | USA |
 |
Axsome Therapeutics
AXSM
|
$ 162.28 | -0.98 % | $ 8.07 B | Nasdaq Global Market,SPB | USA |
 |
Allena Pharmaceuticals
ALNA
|
- | 3.16 % | $ 1.9 M | Nasdaq Global Select Market | USA |
 |
Aytu BioScience
AYTU
|
$ 2.56 | -0.58 % | $ 16.1 M | Nasdaq Capital Market | USA |
 |
Aileron Therapeutics
ALRN
|
- | 10.36 % | $ 9.8 M | Nasdaq Global Select Market | USA |
 |
AlloVir
ALVR
|
- | 4.14 % | $ 49.1 M | Nasdaq Global Select Market | USA |
 |
Alpine Immune Sciences
ALPN
|
- | - | $ 2.17 B | Nasdaq Global Market | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.